MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from long-termdebt, net of issuance...$24,467K Issuance of class aordinary shares, net of...$6,007K Proceeds from optionsexercised-Equity Incentive Plan$170K Proceeds from maturitiesof short-term...$59,166K Net cash flowprovided by financing...$30,644K Net cash flowprovided by investing...$98K Canceled cashflow$59,068K Net change in cashand cash...-$36,027K Canceled cashflow$30,742K Share-based compensationexpense$13,355K Accrued expenses andother current...$7,123K Depreciation andamortization$845K Other non-cash items-$422K Net periodicpension benefit gain...$11K Purchase of short-termmarketable debt securities$59,068K Net cash flow used inoperating activities-$66,286K Canceled cashflow$21,756K Effect of movements inexchange rates on cash...-$483K Net loss-$69,707K Prepaid expenses$10,100K Trade and otherpayables-$6,173K Other receivables$894K Other non-currentassets$749K Operating leaseliabilities-$389K Operating leaseright-of-use assets$30K
Cash Flow

MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics (MLTX)

source: myfinsight.com